ALTERITY THERAPEUTICS-ADR(NASDAQ:ATHE) stock News

ATHE Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: FMFC PKE APDN VNRX ...

Thursday's after hours session: top gainers and losers

3 days ago - By: Benzinga - Mentions: SSII DBVT NDRA RCKT ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

8 days ago - By: Benzinga - Mentions: KIDS VNRX JAGX CUE ...

12 Health Care Stocks Moving In Thursday's After-Market Session

8 days ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

8 days ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

15 days ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

15 days ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

a month ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

a month ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

a month ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

a month ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

2 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Present at the Biotech Showcase

2 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Present at the Biotech Showcase

3 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

3 months ago - By: ALTERITY THERAPEUTICS LIMITED

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

3 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

3 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

3 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

3 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

4 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

4 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Prominently Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Prominently Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

ALTERITY THERAPEUTICS-ADR (ATHE) Stock News

ATHE Latest News, Press Relases and Analysis